Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019
16 avr. 2019 08h15 HE
|
Delcath Systems, Inc.
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
28 févr. 2019 10h38 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
08 févr. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
18 déc. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15 oct. 2018 10h57 HE
|
Delcath Systems, Inc.
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath...
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15 oct. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
26 sept. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Data on Delcath’s PHP Therapy presented at CIRSE 2018
24 sept. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
23 août 2018 11h14 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
21 août 2018 08h52 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...